Companies that are consideredmicro-capconsist mostly of penny stocks—this category denotes companies with market capitalizations between $50 million to $300 million.7For instance, a lesser-known pharma company with no marketable product and working on developing a drug for an incurable disease, or a five-person company working on artificial intelligence (AI)-powered robotics technology may be listed with a small valuation and limited trading activity.
While the upward potential of such companies is high if they succeed, the downside potential is equally worse if they completely fail. Investments in such companies may not be for the faint-hearted and require more due diligence.
Micro Cap의 시가 총액이 약 $50M ~ $300M 이니까
딱 이수준이다
참고로 마이크로 캡 종목은
우리가 흔히말하는 스몰캡보다 더 작은것을 말하며
스몰캡은 미국기준으로 $300M ~ $2B 수준이다
그럼 기사를 보자
Danimer Scientific Announces Successful Expansion of Rinnovo® Demonstration Plant Capacity
쉽게 말해 대니머 사이언티픽이 증설을 완료했다는 것이고 PHA의 일종인 Rinnovo에 대한 증설을 완료했다는 것인데
Rinnovo®는 열 촉매 공정을 사용하여 합성된 폴리하이드록시알카노에이트(PHA)의 한 유형으로, 회사는 이 공정을 통해 다른 발효 공정을 통해 생산되는 PHA보다 더 낮은 비용으로 생산될 수 있다는 것
이를통해 파트너십을 강화 또는 파트너사를 위한 테스트를 더 강화할 수 있다는 것
확장된 데모 설비를 연속 운영할 때, 생산량은 연간 20톤을 기록하며,
이는 이전 생산 능력에 비해 약 20배 규모로 확장된 것인데
확장 프로젝트의 주요 기능은 큰 카보닐화 반응기, 세 개의 추가 분획 증류탑, 큰 중합 반응기 및 폴리머 건조 장치의 설치를 포함하고 있음.
Rinnovo 데모 설비에는 또한 상업용 공장 설계의 추가 공정 조건 테스트 및 최적화를 지원하는
향상된 제어 및 데이터 수집 기능이 있음
Rinnovo 설비 증설이 완료되어
폴리머 플랫폼에 대한 오프테이크 약정을 확보하기 위한 노력을 가속화 할 수 있음
Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, today announced it has successfully completed the expansion of its Rochester, NY demonstration plant in order to better serve partners for the testing of Rinnovo ® polymers.
Rinnovo®is a type of polyhydroxyalkanoate (“PHA”) synthesized using a thermocatalytic process, which the Company believes can be produced at a lower cost than PHA produced via fermentation processes. The Rinnovo®product platform boasts unique properties relative to currently marketed PHA materials, including enhanced barrier properties, increased elongation and a lower melting temperature. Danimer expects the capital cost to build out future commercial capacity of Rinnovo®will be significantly less than commercial plants using fermentation processes to produce other types of PHAs.
When operated continuously, the expanded demonstration plant can produce 20 tonnes annually, which marks an approximate 20x scale up from the previous production capacity. Key features of the expansion project include a larger carbonylation reactor, installation of three additional fractional distillation towers, a larger polymerization reactor and a polymer drying unit. The demonstration plant also features enhanced controls and data collection that will support additional process condition testing and optimization of the commercial plant design.
Stephen E. Croskrey, Chief Executive Officer of Danimer, said, “We are thrilled to have the Rinnovo®demonstration plant expansion completed, allowing us to accelerate our efforts to gain offtake commitments for this exciting polymer platform. Further, I would like to commend the entire Danimer team in Rochester for their efforts to bring the facility on line safely and within budget.”
